Clinical trials: Metastatic Ovary Cancer
Solid Tumor, Metastatic Ovary Cancer
A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of TJ037130 in participants with advanced or metastatic solid tumors, and to determine the Potential Optimal Biological Dose (POBD) of TJ037130 for…
- Conditions
- Solid Tumor, Metastatic Ovary Cancer, Metastatic Gastric Cancer, Metastatic Endometrial Carcinoma
- Trial name
- NCT07715747
- Testing
- TJ037130
- Where
- China
- Volunteers
- 128 people
- Sponsor
- TJ Biopharma Co., Ltd.
Metastatic Cancer, Metastatic Breast Cancer
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer.
- Conditions
- Metastatic Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Metastatic Gastric Cancer
- Trial name
- CHANCES (NCT05143970)
- Testing
- IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Institut Paoli-Calmettes
Sarcoma, Synovial, Sarcoma,Soft Tissue
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
A Phase I/II Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers
- Conditions
- Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV, Triple Negative Breast Cancer
- Trial name
- NCT05296564
- Testing
- CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Hadassah Medical Organization
Breast Cancer, Pancreas Cancer
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
- Conditions
- Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer
- Trial name
- NCT03199586
- Testing
- NP-G2-044
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Novita Pharmaceuticals, Inc.
Prostate Cancer, Breast Cancer
Measuring Oncological Value of Exercise and Statin
The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to…
- Conditions
- Prostate Cancer, Breast Cancer, Kidney Cancer, Ovarian Cancer
- Trial name
- MOVES (NCT05796973)
- Testing
- Guided physical exercise, Atorvastatin, Independent exercise
- Where
- Finland
- Volunteers
- 240 people
- Sponsor
- Tampere University Hospital
Colorectal Cancer, Colorectal Neoplasms
Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet
Bowel obstruction is a common complication in patients with ovarian, peritoneal and bowel cancer due to a mass or spread of disease, causing narrowing to the gut, as these cancers can grow on the bowel surface.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma
- Trial name
- BOUNCED (NCT04898842)
- Testing
- Dietary intervention
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Renal Cell Carcinoma Metastatic, Breast Cancer
Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy
The purpose of the CAPABLE study is to compare health-related quality of life in renal cell carcinoma patients who use or do not use a mobile-based application to monitor adverse events for cancer treatment at home.
- Conditions
- Renal Cell Carcinoma Metastatic, Breast Cancer, Head and Neck Cancer, Thyroid Cancer
- Trial name
- CAPABLE-IT (NCT06161233)
- Testing
- CAPABLE cohort
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other…
- Conditions
- Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid
- Trial name
- PUTNET (NCT04276597)
- Testing
- 177Lu-DOTATOC
- Where
- United States
- Sponsor
- Excel Diagnostics and Nuclear Oncology Center
Metastatic Cancer, Cancer, Breast
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Sarcopenia is defined as reduction in muscle mass and function according to the criteria of the European Working Group on Sarcopenia in older people.
- Conditions
- Metastatic Cancer, Cancer, Breast, Cancer Colon, Cancer, Rectum
- Trial name
- SPACE2 (NCT05154474)
- Testing
- Standard
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Weprom
Cancer, Breast, Cancer, Metastatic
Guided Imagery & Music in Cancer
This is an RCT pilot study to explore the potential effects of the Guided Imagery \& Music method for women with breast or gynecologic cancer, during active treatment.
- Conditions
- Cancer, Breast, Cancer, Metastatic, Cancer Ovaries, Cancer Uterus Cervix
- Trial name
- NCT03936075
- Testing
- the Guided Imagery and Music method, standard care and verbal counselling
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- Aalborg University